Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization

One complication of uveitis which is driven by an increase in VEGF is the formation of inflammatory ocular neovascularization (ION). Here, we analyze the therapeutic role of intravitreal bevacizumab in ION not responding to standard therapy (systemic and ocular corticosteroids and systemic immunosuppressants) in a multicenter retrospective study.The natural history of subfoveal choroidal new vessels histoplasmosis, multifocal choroiditis, Harada and other inflammatory chorioretinal disorders has been very guarded, but with this new approach, we hope to stop the visual loss in these relatively young patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neovascularization Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Harada Toxoplasmosis Histoplasmosis Infections Metaplasia Multifocal Serpiginous Choroiditis Mycobacterium Infections Mycoses Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Tuberculosis

Sex eligibility

All sexes

Study type

Observational

Primary location

American University of Beirut

Beirut, 1136044, Lebanon

About this study

Members of the American Society of Retinal specialists, the American Uveitis Society and the International Uveitis Society were invited to contribute their consecutive cases of ION not responding to standard therapy (corticosteroids (CST) 4 or immunosuppression) and treated with intravitreal anti-VEGF agents. Cases with concomitant or prior cystoid macular edema, diabetes mellitus, or age-related macular degeneration were excluded. Most of the patients had initially been treated in a stepwise fashion with high doses of oral CST, with or without intraocular or subtenon CST or immunosuppressive therapy (as monitored by a rheumatologist). All patients opted to intravitreal anti-VEGF treatment after detailed information about the limited experience, potential side effects and the off-label character of the drug. The risks and benefits of intravitreal therapy were discussed with the patients (or their guardians) who signed an informed consent. Primary outcome measure: Best corrected visual acuity measured as logMAR. Secondary outcome measures:macular thickness on OCT, and stoppage of leakage by IVFA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inflammatory ocular neovascularization (INO)

Exclusion criteria

Eyes with age-related macular degeneration
Diabetes mellitus
Prior cystoid macular edema
Uncontrolled systemic hypertension
Cardiovascular disease

Treatment and study plan

Primary outcomes

Best corrected visual acuity gain after bevacizumab therapy.

Time frame: 3 month, 1 year, 2 year

Secondary outcomes

fluorescein leakage of ocular neovascularization by fluorescein angiography and macular thickness by Optical Computed tomography.

Time frame: 3 month

Sponsors and collaborators

Lead sponsor

Rafic Hariri University Hospital

Other

Collaborators

Heidelberg University
University Hospital Freiburg
University Hospital Tuebingen

Registry information

Official study title

Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization: Multicenter Collaborative Study

Acronym: AVA-ION

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Mar 28, 2008
Registry last updated: Mar 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed